Watch this CME/CE-certified on-demand Webcast to hear expert insights on optimal management of inflammatory bowel disease, strategies for achieving deep remission, and the latest data on biologics and JAK inhibitors. Get answers to:
- Which IBD agents best balance efficacy and safety?
- Is step-up or induction therapy preferable in moderate to severe UC?
- What is the recommended approach for TNF-refractory UC?
More Information
Learning objectives
At the conclusion of this activity, learners should be able to:
- Develop initial IBD treatment strategies with the goal to achieve early deep remission in patients with moderate to severe disease
- Consider the latest outcomes data on non-TNF inhibitor biologics or JAK inhibitors when considering switch therapy for patients who do not achieve sustained remission with conventional or TNF inhibitor regimens
- Compare and contrast JAK inhibitor selectivity for specific JAK enzymes and how these distinctions may potentially relate to safety outcomes
- Explore evidence-based strategies for IBD treatment de-escalation that may include dose reduction or drug discontinuation once sustained remission has been achieved
Faculty
Uma Mahadevan, MD, AGAF
Professor of Medicine
Division of Gastroenterology
Department of Medicine
University of California, San Francisco
Co-Director
UCSF Center for Colitis and Crohn's Disease
San Francisco, California
William J. Sandborn, MD, AGAF
Professor of Medicine
Director, Inflammatory Bowel Disease Center
Division of Gastroenterology
University of California San Diego and UC San Diego Health System
La Jolla, California
Pricing
|
Member
Only |
Nonmember
|
| $Free |
$Free |
